文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

高危淋巴结风险前列腺癌盆腔放疗加量策略的2期前瞻性试验结果

Outcomes of pelvic radiotherapy with boost strategies in high nodal-risk prostate cancer: A phase 2 prospective trial.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-04-23

中位随访7.8年,5年生化无进展生存率为76%,总生存率为95%,急性≥2级泌尿和胃肠毒性分别为33%和23%,患者报告长期泌尿和肠道困扰低。

要点

  • 全盆腔放疗联合靶向加量耐受性良好,5年总生存率95%。
  • 全队列5年生化无进展生存率76%,RECIST阳性淋巴结者结果更差。
  • 仅42例接受前列腺内加量,凸显影像判读和勾画标准化的挑战。

核心结论

  • 全盆腔放疗联合靶向剂量递增耐受性良好,患者报告长期泌尿和肠道困扰低。
  • 较高比例患者未接受前列腺内加量,提示方法学挑战并强调需标准化影像判读和勾画指南。

研究设计与样本

  • 放疗方案:前列腺77 Gy、盆腔淋巴结56 Gy,35次分割;PET阳性淋巴结加量至70 Gy,MRI定义的前列腺内病灶可行时加量至84 Gy。

主要发现

  • 全队列5年生化无进展生存率为76%,RECIST阳性淋巴结受累患者结果更差。
  • 5年总生存率为95%。
  • 急性≥2级泌尿生殖毒性和胃肠道毒性分别发生于33%和23%的患者,且随时间下降。
  • 未观察到≥3级胃肠道毒性。
  • 患者报告结局显示长期泌尿和肠道困扰低。

临床怎么用

  • 可考虑对高危淋巴结风险前列腺癌行全盆腔放疗并针对PET阳性淋巴结和MRI识别的前列腺内病灶加量。
  • 治疗中需关注急性泌尿生殖和胃肠道毒性,并采用标准化影像判读和勾画以保证加量实施。

局限性

  • 较高比例患者未接受前列腺内加量,可能影响对加量策略效果的解读。
  • 研究为2期前瞻性试验,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVE: The optimal radiotherapy strategy for prostate cancer (PC) patients with high nodal risk remains debated. This prospective phase II study reports long‑term clinical outcomes, toxicity, and patient‑reported outcomes in men with PC treated with whole‑pelvis radiotherapy and dose escalation to MRI‑identified intraprostatic lesions and PET‑positive pelvic lymph nodes. MATERIALS/METHODS: Eighty‑five PC patients with high nodal risk or up to three pelvic nodal metastases were enrolled between 2013 and 2017. Radiotherapy delivered 77 Gy to the prostate and 56 Gy to pelvic nodes in 35 fractions, with escalation to 70 Gy for PET‑positive nodes and 84 Gy for MRI‑defined intraprostatic lesions when feasible. Endpoints included biochemical progression‑free survival, overall survival, toxicity, and longitudinal patient‑reported outcomes. RESULTS: Seventy-eight patients underwent radiotherapy. Of these, 42 received an intraprostatic boost and were classified as the per-protocol population. Median follow‑up was 7.8 years, and 26% had N1 disease. For the full cohort, five‑year biochemical progression‑free survival was 76%, with poorer results among patients with RECIST‑positive nodal involvement. Five‑year overall survival was 95%. Acute grade ≥ 2 genitourinary and gastrointestinal toxicities occurred in 33 and 23%, respectively, and decreased over time. No grade ≥ 3 gastrointestinal toxicity was observed. Patient‑reported outcomes showed low long‑term urinary and bowel bother. CONCLUSION: Whole‑pelvis radiotherapy with targeted dose escalation was well tolerated. The high proportion of patients not receiving an intraprostatic boost underscores methodological challenges and emphasises the need for standardised imaging interpretation and delineation guidelines.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Thellenberg Karlsson C, Notstam K, Tavelin B, et al. Outcomes of pelvic radiotherapy with boost strategies in high nodal-risk prostate cancer: A phase 2 prospective trial. Clin Transl Radiat Oncol. 2026. PMID: 42088776. doi:10.1016/j.ctro.2026.101175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。